Different Antiplatelet Therapy Strategy After Minimally Invasive Cardiac Surgery for Coronary Artery Bypass Graft Surgery (DATA-MIDCAB)

A Randomized Controled Trial: Different Antiplatelet Therapy Strategy After Minimally Invasive Cardiac Surgery for Coronary Artery Bypass Graft Surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000028841

Enrollment

Unknown

Registered

2020-01-05

Start date

2020-01-13

Completion date

Unknown

Last updated

2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Group 1:Ticagrelor (90 mg bid)

Group 2:Aspirin(100 mg qd)

Group 3:ticagrelor (90 mg bid) and Aspirin(100 mg qd)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Aged < 75 years; CHD patietns with indications for elective (MICS-CABG) surgery; Willing to sign informed consent and cooperate with follow-up.

Exclusion criteria

Exclusion criteria: 1. Congestive heart failure,with NYHA class III-IV; 2. Active cancer, current HIV infection, severe liver, renal or pulmanary impairment; 3. Life expectancy < 12 months; 4. Participation in another investigational drug or device study in the last 30 days.

Design outcomes

Primary

Measure	Time frame
ratio of vessels open without bleeding;	—

Countries

China

Contacts

Public ContactWang Yupeng

Peking University Third Hospital

wangyp007@163.com+86 15600568206

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026